<DOC>
	<DOC>NCT00300053</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of intramyocardial injections of adult stem cells in patients with refractory chronic myocardial ischemia.</brief_summary>
	<brief_title>ACT34-CMI -- Adult Autologous CD34+ Stem Cells</brief_title>
	<detailed_description>This is a double-blind, prospective, randomized, placebo-controlled trial to determine the tolerability, efficacy, safety and dose range of intramyocardial injections of adult autologous CD34+ cells mobilized with granulocyte colony stimulating factor for the reduction of angina episodes in patients with refractory chronic myocardial ischemia.</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>2180 years of age CCS functional class III or IV chronic refractory angina unsuitable for conventional revascularization predominant congestive heart failure left ventricular ejection fraction of less than 25% at screening myocardial infarction within 60 days of treatment successful coronary revascularization within 6 months of study enrollment history of moderate to severe aortic stenosis or prosthetic aortic valve comorbidity associated with life expectancy of less than 1 year</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>angina</keyword>
</DOC>